Enhanced Akt phosphorylation and myogenic differentiation in PI3K p110β-deficient myoblasts is mediated by PI3K p110α and mTORC2

Growth Factors

Volumn 30, Issue 6, 2012, Pages 367-384

  Matheny, Ronald W ^a   Lynch, Christine M ^a   Leandry, Luis A ^a  

^a U S ARMY RESEARCH INSTITUTE OF ENVIRONMENTAL MEDICINE   (United States)

Author keywords

Akt; MTOR; Myoblast; Myogenesis; PI3K

Indexed keywords

COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR; LYSOPHOSPHATIDIC ACID; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P110; PROTEIN P110BETA; SMALL INTERFERING RNA; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; ENZYME ACTIVATION; ENZYME INHIBITION; GENE SILENCING; IMMUNOREACTIVITY; MUSCLE DEVELOPMENT; MYOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84871092733     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2012.734507     Document Type: Article

References (86)

1. Adams GR. 2006. Satellite cell proliferation and skeletal muscle hypertrophy. Appl Physiol Nutr Metab 31:782-790.
2. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA. 1996. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15:6541-6551. (Pubitemid 26413787)
3. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P. 1997. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 7:261-269. (Pubitemid 27176852)
4. Barnett SF, Defeo-Jones D, Fu S, Hancock PJ, Haskell KM, Jones RE, Kahana JA, Kral AM, Leander K, Lee LL, Malinowski J, McAvoy EM, Nahas DD, Robinson RG, Huber HE. 2005. Identification and characterization of pleckstrin-homology- domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J 385:399-408. (Pubitemid 40165072)
5. Bentzinger CF, Romanino K, Cloetta D, Lin S, Mascarenhas JB, Oliveri F, Xia J, Casanova E, Costa CF, Brink M, Zorzato F, Hall MN, Ruegg MA. 2008. Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metab 8:411-424.
6. Boulbes DR, Shaiken T, Sarbassov dos D. 2011. Endoplasmic reticulum is a main localization site of mTORC2. Biochem Biophys Res Commun 413:46-52.
7. Bozulic L, Surucu B, Hynx D, Hemmings BA. 2008. PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell 30:203-213. (Pubitemid 351626686)
8. Brachmann SM, Ueki K, Engelman JA, Kahn RC, Cantley LC. 2005. Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. Mol Cell Biol 25:1596-1607. (Pubitemid 40282598)
9. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
10. Brodbeck D, Cron P, Hemmings BA. 1999. A human protein kinase Bgamma with regulatory phosphorylation sites in the activation loop and in the C-terminal hydrophobic domain. J Biol Chem 274:9133-9136.
11. Brognard J, Sierecki E, Gao T, Newton AC. 2007. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms.Mol Cell 25: 917-931. (Pubitemid 46436532)
12. Charge SB, Rudnicki MA. 2004. Cellular and molecular regulation of muscle regeneration. Physiol Rev 84:209-238. (Pubitemid 38049880)
13. Cho H, Thorvaldsen JL, Chu Q, Feng F, Birnbaum MJ. 2001. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 276: 38349-38352.
14. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB, 3rd., Kaestner KH, Bartolomei MS, Shulman GI, Birnbaum MJ. 2001. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292: 1728-1731. (Pubitemid 32506248)
15. Ciraolo E, Iezzi M, Marone R, Marengo S, Curcio C, Costa C, Azzolino O, Gonella C, Rubinetto C, Wu H, Dastru W, Martin EL, Silengo L, Altruda F, Turco E, Lanzetti L, Musiani P, Ruckle T, Rommel C, Backer JM, Forni G, Wymann MP, Hirsch E. 2008. Phosphoinositide 3-kinase p110beta activity: Key role in metabolism and mammary gland cancer but not development. Sci Signal 1:ra3.
16. Copp J, Manning G, Hunter T. 2009. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): Phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res 69:1821-1827.
17. Dalle Pezze P, Sonntag AG, Thien A, Prentzell MT, Godel M, Fischer S, Neumann-Haefelin E, Huber TB, Baumeister R, Shanley DP, Thedieck K. 2012. A dynamic network model of mTOR signaling reveals TSC-independent mTORC2 regulation. Sci Signal 5:ra25.
18. Easton RM, Cho H, Roovers K, Shineman DW, Mizrahi M, Forman MS, Lee VM, Szabolcs M, de Jong R, Oltersdorf T, Ludwig T, Efstratiadis A, Birnbaum MJ. 2005. Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol 25:1869-1878. (Pubitemid 40280150)
19. Ewton DZ, Florini JR. 1981. Effects of the somatomedins and insulin on myoblast differentiation in vitro. Dev Biol 86:31-39. (Pubitemid 11021741)
20. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM. 2009. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7:e38.
21. Feng J, Park J, Cron P, Hess D, Hemmings BA. 2004. Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNAdependent protein kinase. J Biol Chem 279:41189-41196. (Pubitemid 39287721)
22. Florini JR, Magri KA, Ewton DZ, James PL, Grindstaff K, Rotwein PS. 1991. "Spontaneous" differentiation of skeletal myoblasts is dependent upon autocrine secretion of insulin-like growth factor-II. J Biol Chem 266:15917-15923. (Pubitemid 21907745)
23. Foukas LC, Shepherd PR. 2004. Phosphoinositide 3-kinase: The protein kinase that time forgot. Biochem Soc Trans 32:330-331. (Pubitemid 38582120)
24. Foukas LC, Claret M, PearceW, Okkenhaug K, Meek S, Peskett E, Sancho S, Smith AJ, Withers DJ, Vanhaesebroeck B. 2006. Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441:366-370. (Pubitemid 44050203)
25. Franke TF, Kaplan DR, Cantley LC, Toker A. 1997. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 275:665-668. (Pubitemid 27061333)
26. Frias MA, Thoreen CC, Jaffe JD, Schroder W, Sculley T, Carr SA, Sabatini DM. 2006. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 16:1865-1870. (Pubitemid 44354144)
27. Gan X,Wang J, Su B,Wu D. 2011. Evidence for direct activation of mTORC2 kinase activity by phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 286:10998-11002.
28. Gao T, Furnari F, Newton AC. 2005. PHLPP: A phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18:13-24. (Pubitemid 40444644)
29. Guillermet-Guibert J, Bjorklof K, Salpekar A, Gonella C, Ramadani F, Bilancio A, Meek S, Smith AJ, Okkenhaug K, Vanhaesebroeck B. 2008. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci USA 105:8292-8297. (Pubitemid 351904749)
30. Guo JP, Coppola D, Cheng JQ. 2011. IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation. J Biol Chem 286:37389-37398.
31. Halevy O, Cantley LC. 2004. Differential regulation of the phosphoinositide 3-kinase and MAP kinase pathways by hepatocyte growth factor vs. insulin-like growth factor-I in myogenic cells. Exp Cell Res 297:224-234. (Pubitemid 38759575)
32. Hayakawa M, Kaizawa H, Moritomo H, Koizumi T, Ohishi T, Okada M, Ohta M, Tsukamoto S, Parker P, Workman P, Waterfield M. 2006. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem 14: 6847-6858. (Pubitemid 44307656)
33. Hill MM, Feng J, Hemmings BA. 2002. Identification of a plasma membrane Raft-associated PKB Ser473 kinase activity that is distinct from ILK and PDK1. Curr Biol 12:1251-1255. (Pubitemid 34801175)
34. Hirsch E, Costa C, Ciraolo E. 2007. Phosphoinositide 3-kinases as a common platform for multi-hormone signaling. J Endocrinol 194:243-256. (Pubitemid 47249663)
35. Hong-Brown LQ, Brown CR, Navaratnarajah M, Huber DS, Lang CH. 2011. Alcohol-induced modulation of rictor and mTORC2 activity in C2C12 myoblasts. Alcohol Clin Exp Res 35:1445-1453.
36. Hresko RC, Mueckler M. 2005. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 280:40406-40416. (Pubitemid 41780527)
37. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J, Su B. 2006. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127:125-137. (Pubitemid 44466632)
38. Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH. 2005. PI3-kinase p110beta: A new target for antithrombotic therapy. Nat Med 11:507-514. (Pubitemid 40685973)
39. Jean-Baptiste G, Yang Z, Khoury C, Greenwood MT. 2005. Lysophosphatidic acid mediates pleiotropic responses in skeletal muscle cells. Biochem Biophys Res Commun 335:1155-1162. (Pubitemid 41215539)
40. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ. 2008. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454:776-779.
41. Jiang BH, Zheng JZ, Vogt PK. 1998. An essential role of phosphatidylinositol 3-kinase in myogenic differentiation. Proc Natl Acad Sci USA 95:14179-14183. (Pubitemid 28549341)
42. Jiang BH, Aoki M, Zheng JZ, Li J, Vogt PK. 1999. Myogenic signaling of phosphatidylinositol 3-kinase requires the serinethreonine kinase Akt/protein kinase B. Proc Natl Acad Sci USA 96:2077-2081. (Pubitemid 29117870)
43. Karalaki M, Fili S, Philippou A, Koutsilieris M. 2009. Muscle regeneration: Cellular and molecular events. In Vivo 23:779-796.
44. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM. 2006. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125:733-747.
45. Kuang S, Rudnicki MA. 2008. The emerging biology of satellite cells and their therapeutic potential. Trends MolMed 14:82-91.
46. Kuang S, Gillespie MA, Rudnicki MA. 2008. Niche regulation of muscle satellite cell self-renewal and differentiation. Cell Stem Cell 2:22-31.
47. Lin ME, Herr DR, Chun J. 2010. Lysophosphatidic acid (LPA) receptors: Signaling properties and disease relevance. Prostaglandins Other Lipid Mediat 91:130-138.
48. Maier U, Babich A, Nurnberg B. 1999. Roles of non-catalytic subunits in gbetagamma-induced activation of class I phosphoinositide 3-kinase isoforms beta and gamma. J Biol Chem 274: 29311-29317.
49. Manning BD, Cantley LC. 2007. AKT/PKB signaling: Navigating downstream. Cell 129:1261-1274. (Pubitemid 46962095)
50. Maroulakou IG, Oemler W, Naber SP, Klebba I, Kuperwasser C, Tsichlis PN. 2008. Distinct roles of the three Akt isoforms in lactogenic differentiation and involution. J Cell Physiol 217: 468-477.
51. Marques M, Kumar A, Cortes I, Gonzalez-Garcia A, Hernandez C, Moreno-Ortiz MC, Carrera AC. 2008. Phosphoinositide 3-kinases p110alpha and p110beta regulate cell cycle entry, exhibiting distinct activation kinetics in G1 phase. Mol Cell Biol 28:2803-2814. (Pubitemid 351542377)
52. Marques M, Kumar A, Poveda AM, Zuluaga S, Hernandez C, Jackson S, Pasero P, Carrera AC. 2009. Specific function of phosphoinositide 3-kinase beta in the control of DNA replication. Proc Natl Acad Sci USA 106:7525-7530.
53. Matheny RW, Jr, Adamo ML. 2009a. Role of Akt isoforms in IGF-Imediated signaling and survival in myoblasts. Biochem Biophys Res Commun 389:117-121.
54. Matheny RW, Jr, Adamo ML. 2009. Effects of PI3K catalytic subunit and Akt isoform deficiency on mTOR and p70S6K activation in myoblasts. Biochem Biophys Res Commun 390: 252-257.
55. Matheny RW, Jr, Adamo ML. 2010. PI3K p110 alpha and p110 beta have differential effects on Akt activation and protection against oxidative stress-induced apoptosis in myoblasts. Cell Death Differ 17:677-688.
56. Matheny RW, Jr, Nindl BC. 2011. Loss of IGF-IEa or IGF-IEb impairs myogenic differentiation. Endocrinology 152: 1923-1934.
57. Mauro A. 1961. Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol 9:493-495.
58. Minetti GC, Feige JN, Rosenstiel A, Bombard F, Meier V,Werner A, Bassilana F, Sailer AW, Kahle P, Lambert C, Glass DJ, Fornaro M. 2011. Galphai2 signaling promotes skeletal muscle hypertrophy, myoblast differentiation, and muscle regeneration. Sci Signal 4:ra80.
59. Moolenaar WH. 1995. Lysophosphatidic acid, a multifunctional phospholipid messenger. J Biol Chem 270:12949-12952.
60. Murga C, Fukuhara S, Gutkind JS. 2000. A novel role for phosphatidylinositol 3-kinase beta in signaling from G proteincoupled receptors to Akt. J Biol Chem 275:12069-12073. (Pubitemid 30237781)
61. Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, Yancopoulos GD, Glass DJ. 2001. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 3:1009-1013. (Pubitemid 34428746)
62. Rotwein P, Wilson EM. 2009. Distinct actions of Akt1 and Akt2 in skeletal muscle differentiation. J Cell Physiol 219:503-511.
63. Samuels Y,Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. 2004. High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554. (Pubitemid 38541907)
64. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. 2005. Phosphorylation and regulation of Akt/PKB by the rictormTOR complex. Science 307:1098-1101. (Pubitemid 40262113)
65. Scheid MP, Marignani PA, Woodgett JR. 2002. Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B. Mol Cell Biol 22:6247-6260. (Pubitemid 34857843)
66. Shah BH, Neithardt A, Chu DB, Shah FB, Catt KJ. 2006. Role of EGF receptor transactivation in phosphoinositide 3-kinase-dependent activation of MAP kinase by GPCRs. J Cell Physiol 206:47-57. (Pubitemid 41740716)
67. Sharples AP, Stewart CE. 2011. Myoblast models of skeletal muscle hypertrophy and atrophy. Curr Opin Clin Nutr Metab Care 14: 230-236.
68. Shi X, Garry DJ. 2006. Muscle stem cells in development, regeneration, and disease. Genes Dev 20:1692-1708. (Pubitemid 43992877)
69. Shu L, Houghton PJ. 2009. The mTORC2 complex regulates terminal differentiation of C2C12 myoblasts. Mol Cell Biol 29: 4691-4700.
70. Soliman GA, Acosta-Jaquez HA, Dunlop EA, Ekim B, Maj NE, Tee AR, Fingar DC. 2010. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem 285:7866-7879.
71. Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CB, Painter GF, Holmes AB, McCormick F, Hawkins PT. 1997. Dual role of phosphatidylinositol-3,4, 5-trisphosphate in the activation of protein kinase B. Science 277:567-570. (Pubitemid 27369005)
72. Surucu B, Bozulic L, Hynx D, Parcellier A, Hemmings BA. 2008. In vivo analysis of protein kinase B (PKB)/Akt regulation in DNA-PKcs-null mice reveals a role for PKB/Akt in DNA damage response and tumorigenesis. J Biol Chem 283: 30025-30033.
73. Toker A, Newton AC. 2000. Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J Biol Chem 275:8271-8274. (Pubitemid 30180163)
74. Tureckova J,Wilson EM, Cappalonga JL, Rotwein P. 2001. Insulinlike growth factor-mediated muscle differentiation: Collaboration between phosphatidylinositol 3-kinase-Akt-signaling pathways and myogenin. J Biol Chem 276:39264-39270.
75. Utermark T, Rao T, Cheng H, Wang Q, Lee SH, Wang ZC, Iglehart JD, Roberts TM, Muller WJ, Zhao JJ. 2012. The p110alpha and p110beta isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes Dev 26:1573-1586.
76. Vanhaesebroeck B, Waterfield MD. 1999. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 253: 239-254.
77. Vogt PK, Gymnopoulos M, Hart JR. 2009. PI3-kinase and cancer: Changing accents. Curr Opin Genet Dev 19:12-17.
78. Warfel NA, Niederst M, Newton AC. 2011. Disruption of the interface between the pleckstrin homology (PH) and kinase domains of Akt protein is sufficient for hydrophobic motif site phosphorylation in the absence of mTORC2. J Biol Chem 286: 39122-39129.
79. Wick MJ, Dong LQ, Riojas RA, Ramos FJ, Liu F. 2000. Mechanism of phosphorylation of protein kinase B/Akt by a constitutively active 3-phosphoinositide-dependent protein kinase-1. J Biol Chem 275:40400-40406. (Pubitemid 32064675)
80. Winter JN, Jefferson LS, Kimball SR. 2011. ERK and Akt signaling pathways function through parallel mechanisms to promote mTORC1 signaling. Am J Physiol Cell Physiol 300: C1172-C1180.
81. Winter JN, Fox TE, Kester M, Jefferson LS, Kimball SR. 2010. Phosphatidic acid mediates activation of mTORC1 through the ERK signaling pathway. Am J Physiol Cell Physiol 299: C335-C344.
82. Xie X, ZhangD, Zhao B, Lu M-K, YouM, Condorelli G,Wang C-Y, Guan K-L. 2011. IkB kinase e and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proc Natl Acad Sci USA 108:6474-6479.
83. Yart A, Roche S, Wetzker R, Laffargue M, Tonks N, Mayeux P, Chap H, Raynal P. 2002. A function for phosphoinositide 3-kinase beta lipid products in coupling beta gamma to Ras activation in response to lysophosphatidic acid. J Biol Chem 277: 21167-21178. (Pubitemid 34952252)
84. Yip SC, El-Sibai M, Hill KM, Wu H, Fu Z, Condeelis JS, Backer JM. 2004. Over-expression of the p110beta but not p110alpha isoform of PI 3-kinase inhibits motility in breast cancer cells. Cell Motil Cytoskeleton 59:180-188. (Pubitemid 39435201)
85. Zhao JJ, Cheng H, Jia S, Wang L, Gjoerup OV, Mikami A, Roberts TM. 2006. The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci USA 103:16296-16300. (Pubitemid 44715190)
86. Zinzalla V, Stracka D, Oppliger W, Hall MN. 2011. Activation of mTORC2 by association with the ribosome. Cell 144:757-768.